Uterine leiomyoma with massive lymphoid infiltrate after colon cancer chemotherapy: an immunohistochemical investigation with special reference to lysosome-associated membrane protein expression

• Authors: Veselin Belovejdov , Dorian Dikov , Marie Auriault , Christiane Copie-Bergman , Victoria Sarafian
• Languages of publication: EN

Abstracts

EN

Uterine leiomyoma with massive lymphoid infiltration is a rare morphologic phenomenon. We describe the first case of uterine leiomyoma with lymphoid infiltration observed in a patient after chemotherapy for sigmoid cancer. We performed immunohistochemical analysis with a panel of antibodies to several markers. Detection of CD20, CD3, Ki67, CD68 and Epstein-Barr virus nuclear antigen assisted in the differential diagnosis and partial elucidation of the pathogenesis. In addition, we examined the lysosome-associated membrane proteins LAMP-1 and LAMP-2 for the first time in this lesion. Their expression was elevated, indicating enhanced autophagy, an indirect sign of degenerative changes in this benign tumor characterized by massive lymphoid infiltration.

Keywords

EN

Uterine leiomyoma with massive lymphoid infiltrate; Colon cancer; Immunohistochemistry; LAMPs

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2009
• Volume: 4
• Issue: 1
• Pages: 54-58

Dates

published

1 - 3 - 2009

online

11 - 2 - 2009

Contributors

author

Veselin Belovejdov

• Department of General and Clinical Pathology, Medical University of Plovdiv, 4002, Plovdiv, Bulgaria

author

Dorian Dikov

• Service d’Anatomie et de Cytologie Pathologiques, Centre Hospitalier de Lagny-Marne La-Vallée, 77405, Lagny-Sur-Marne, France

author

Marie Auriault

• Service d’Anatomie et de Cytologie Pathologiques, Centre Hospitalier de Lagny-Marne La-Vallée, 77405, Lagny-Sur-Marne, France

author

Christiane Copie-Bergman

• Département de Pathologie, Hôpital Henri Mondor, 94010, Créteil, France

author

Victoria Sarafian

• Department of Biology, Medical University of Plovdiv, 4002, Plovdiv, Bulgaria

References

• [1] Paik S.S., Oh Y.H., Jang K.S., Han H.X., Cho S.H., Uterine leiomyoma with massive lymphoid infiltration: case report and review of the literature, Pathol. Int., 2004, 54, 343–348 http://dx.doi.org/10.1111/j.1440-1827.2004.01629.x[Crossref]
• [2] Wei S., Feng R., Cui Q., Luo Y., Zhang S., Uterine adenomyoma with lymphoid infiltration simulating lymphoma, Gynecol. Oncol., 2004, 95, 409–411 http://dx.doi.org/10.1016/j.ygyno.2004.07.058[Crossref]
• [3] Saglam A., Guler G., Taskin M., Ayhan A., Uner A., Uterine leiomyoma with prominent lymphoid infiltrate, Int. J. Gynecol. Cancer, 2005, 15, 167–170 http://dx.doi.org/10.1111/j.1048-891x.2005.14431.x[Crossref]
• [4] Ferry J.A., Harris N.L., Scully R.E., Uterine leiomyomas with lymphoid infiltration simulating lymphoma. A report of seven cases, Int. J. Gynecol. Pathol., 1989, 8, 263–270 [Crossref]
• [5] Chuang S.S., Lin C.N., Li C.Y., Wu C.H., Uterine leiomyoma with massive lymphocytic infiltration simulating malignant lymphoma. A case report with immunohistochemical study showing that the infiltrating lymphocytes are cytotoxic T cells, Pathol. Res. Pract., 2001, 197, 135–138
• [6] Botsis D., Trakakis E., Kondis-Pafitis A., Kontoravdis A., Kassanos D., Chryssikopoulos A. et al., Leiomyoma of the uterus with massive lymphoid infiltration simulating lymphoma. A case report, Eur. J. Gynaecol. Oncol., 1999, 20, 61–62
• [7] McClean G., McCluggage W.G., Unusual morphologic features of uterine leiomyomas treated with gonadotropin-releasing hormone agonists: massive lymphoid infiltration and vasculitis, Int. J. Surg. Pathol., 2003, 11, 339–344 http://dx.doi.org/10.1177/106689690301100417[Crossref]
• [8] Ohmori T., Wakamoto R., Lu L.M., Okada K., M. Nose M., Immunohistochemical study of a case of uterine leiomyoma showing massive lymphoid infiltration and localized vasculitis after LH-RH derivant treatment, Histopathology, 2002, 41, 276–277 http://dx.doi.org/10.1046/j.1365-2559.2002.13724.x[Crossref]
• [9] Bardseley V., Cooper P., Peat D., Massive lymphocytic infiltration of uterine leiomyomas associated with GnRN agonist treatment, Histopathology, 1998, 33, 80–83 http://dx.doi.org/10.1046/j.1365-2559.1998.00451.x[Crossref]
• [10] Crow J., Gardner R.L., McSweeney G., Shaw R.W., Morphological changes in uterine leiomyomas treated by GnRH agonist goserelin, Int. J. Gynecol. Pathol., 1995, 14, 235–242 http://dx.doi.org/10.1097/00004347-199507000-00007[Crossref]
• [11] Resta L., Sanguedolce F., Orsini, G., Laricchia L., Piscitelli D., Fiore M.G., Morphometric and histological evaluation of uterine leiomyomas treated with GnRH agonists or progestational agents, Pathologica, 2004, 96, 35–41
• [12] Colgan T.J., Pendergast S., LeBlanc M., The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues, Hum. Pathol., 1993, 24, 1073–1077 http://dx.doi.org/10.1016/0046-8177(93)90186-K[Crossref]
• [13] Ito F., Kawamura N., Ichimura T., Tsujimura A., Ishiko O., Ogita S., Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment, Fertil. Steril., 2001, 75, 125–130 http://dx.doi.org/10.1016/S0015-0282(00)01660-5[Crossref]
• [14] Bozzini N., Rodrigues C., Petti D., Bevilacqua R., Goncalves, S., Pinotti J., Efects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure, Acta Obstet. Gynecol. Scan., 2003 82, 330–334 http://dx.doi.org/10.1034/j.1600-0412.2003.00049.x[Crossref]
• [15] Ueda M., Kumagai K., Ueki K., Inoki C., Orino I., Ueki M., Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5-fluorouracil, Int. J. Cancer, 1997, 71, 668–674 http://dx.doi.org/10.1002/(SICI)1097-0215(19970516)71:4<668::AID-IJC25>3.0.CO;2-6[Crossref]
• [16] Laforga J., Aranda F., Uterine leiomyoma with T-cell infiltration associated with GnRH agonist goserelin, Histopathology, 1999, 34, 471–472 http://dx.doi.org/10.1046/j.1365-2559.1999.0676a.x[Crossref]
• [17] Yoshimatsu K., Kuhara K., Itagaki, H. Aizawa M., Yokomizo H., Fujimoto T., et al., Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer, Anticancer Res., 2008, 21, 373–378
• [18] Cuervo A.M., Dice J.F., Unique properties of lamp 2 compared to other lamp 2 isoforms, J. Cell. Sci., 2000, 24, 4441–4450
• [19] Sarafian V., Dikov D., LAMPs and ABH histo-blood group antigens in granulation tissue, APMIS, 2007, 114, 701–706 http://dx.doi.org/10.1111/j.1600-0463.2007.apm_576.x[WoS][Crossref]
• [20] Gozuacik D., Kimchi A., Autophagy as a cell death and tumor suppressor mechanism, Oncogene, 2004, 23, 2891–2906 http://dx.doi.org/10.1038/sj.onc.1207521[Crossref]
• [21] Huang J., Klionsky D.J., Autophagy and human disease, Cell Cycle, 2007, 6, 1837–1849 [Crossref]

Identifiers

DOI

10.2478/s11536-009-0016-7